Abiopharma

🔍 SETH SANDESH (Director)

Company: Actinium Pharmaceuticals, Inc. (ATNM)

Report Date: 2025-08-18

Detailed Transactions and Holdings:

• Sold 120,900 shares of Common Stock at $1.71 per share (Direct)
  Date: 2025-08-18 | Code: F | equity_swap_involved: 0 | shares_owned_after: 184,481.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: Represents shares of common stock withheld to pay Mr. Seth's tax withholding obligations incurred in connection with the vesting of 300,000 restricted stock units, or RSUs, on August 18, 2025. On August 17, 2022, Mr. Seth was granted an award of 300,000 RSUs, in exchange for warrants granted to Mr. Seth on December 17, 2012 for services provided to the Company prior to becoming employed by Actinium. The warrants were in the money since vesting on December 17, 2013. Mr. Seth refrained from exercising the warrants to be aligned with the long-term interests of the Company and stockholders. In November 2018, the Board extended the expiration of Mr. Seth's warrants to February 2022. In February 2022, the Company requested that Mr. Seth not exercise the warrants. In exchange, the Board determined to grant Mr. Seth 300,000 RSUs based on the average fair value of the warrants during their vested life to continue to align Mr. Seth with the long-term interest of the Company and stockholders.